(function(){
			var content_array=["<p><b>关于<\/b><b>GSK<\/b><b>：<\/b><\/p> \n<p>GSK是一家以科学为导向的全球医疗保健公司，旨在帮助人们能够做到更多、感觉更舒适、生活更长久。如需更多信息，请访问<a href=\"https:\/\/t.prnasia.com\/t\/D9rGh0lz\" target=\"_blank\" rel=\"nofollow\">www.gsk.com<\/a>。<\/p> \n<p><b>参考文献<\/b><\/p> \n<p>1.&nbsp;&nbsp;&nbsp;&nbsp; Chen WQ, Zheng RS, Baade PD,et al. Cancer Statistics in <span class=\"xn-location\">China<\/span>, 2015. CA CANCER J CLIN 2016;00:00–00:1-18<\/p> \n<p>2.&nbsp;&nbsp;&nbsp;&nbsp; Lei T, Mao WM, Lei TH.et al.Incidence and mortality trend of cervical cancer in 11 cancer registries of china.Chin J Cancer Res. 2011 ;23(1):10-4.<\/p> \n<p>3.&nbsp;&nbsp;&nbsp;&nbsp; 中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识&nbsp;[J] . 中华预防医学杂志,2019,53 (8): 761-803. DOI: 10.3760\/cma.j.issn.0253-9624.2019.08.001<\/p> \n<p>4.&nbsp;&nbsp;&nbsp;&nbsp; Global strategy to accelerate the elimination of cervical cancer as a public health problem. <span class=\"xn-location\">Geneva<\/span>: World Health Organization. Licence, 2020. CC BY-NC-SA 3.0 IGO.<\/p> \n<p>5.&nbsp;&nbsp;&nbsp;&nbsp; Puthanakit, T., et al., Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16\/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years. J Infect Dis, 2016. 214(4): p. 525-36.<\/p> \n<p>6.&nbsp;&nbsp;&nbsp;&nbsp; Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule.<\/p> \n<p>7.&nbsp;&nbsp;&nbsp;&nbsp; Romanowski, B., et al., Sustained immunogenicity of the HPV-16\/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother, 2016. 12(1): p. 20-9.<\/p> \n<p>8.&nbsp;&nbsp;&nbsp;&nbsp; 中华预防医学会妇女保健分会. 子宫颈癌综合防控指南. 北京: 人民卫生出版社, 2017.<\/p> \n<p>9.&nbsp;&nbsp;&nbsp;&nbsp; Leroux-Roels G, Marchant A, Levy J, et al. Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. Clin Immunol 2016; 169: 16–27.<\/p> \n<p>10.&nbsp;&nbsp; Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24: 5937–49.<\/p> \n<p>11.&nbsp;&nbsp; Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16\/18 vaccine: Improving upon nature. Gynecol Oncol 2008; 110: S1.<\/p> \n<p>12.&nbsp;&nbsp; GSK. GSK Cervarix<sup>&reg;<\/sup> two-dose schedule receives European marketing authorization <a href=\"https:\/\/t.prnasia.com\/t\/hYakIsUV\" rel=\"nofollow\">https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-cervarix-two-dose-schedule-receives-european-marketing-authorisation\/<\/a><\/p> \n<p>13.&nbsp;&nbsp; Lyseng-Williamson, K.A., Human papillomavirus-16\/18 AS04-adjuvanted vaccine (cervarix(R)): a guide to its two-dose schedule in girls aged 9-14 years in the EU. Paediatr Drugs, 2014. 16(3): p. 247-53.<\/p> \n<p>14.&nbsp;&nbsp; Tay, S.K., et al., Cost-effectiveness of two-dose human papillomavirus vaccination in <span class=\"xn-location\">Singapore<\/span>. Singapore Med J, 2018. 59(7): p. 370-382.<\/p> \n<p>15.&nbsp;&nbsp; Germar, M.J., et al., Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16\/18 vaccine compared with human papillomavirus 6\/<span class=\"xn-chron\">11\/16\/18<\/span> vaccine in <span class=\"xn-location\">the Philippines<\/span>, with the new 2-dose schedule. Hum Vaccin Immunother, 2017. 13(5): p. 1158-1166.<\/p> \n<p>16.&nbsp;&nbsp; Van Kriekinge, G., et al., Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in <span class=\"xn-location\">Malaysia<\/span>. Asian Pac J Cancer Prev, 2018. 19(4): p. 933-940.<\/p> \n<p>17.&nbsp;&nbsp; GSK. GSK internal tracking system for Global Regulatory Affairs.<\/p> \n<p>18.&nbsp;&nbsp; Descamps, D., et al., Safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin, 2009. 5(5): p. 332-40.<\/p> \n<p>19.&nbsp;&nbsp; Angelo, M.G., et al., Pooled analysis of large and long-term safety data from the human papillomavirus-16\/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf, 2014. 23(5): p. 466-79.<\/p> \n<p>20.&nbsp;&nbsp; Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in <span class=\"xn-location\">Scotland<\/span>: retrospective population study. BMJ. 2019 <span class=\"xn-chron\">Apr 3<\/span>;365:l1161. doi: 10.1136\/bmj.l1161.<\/p> \n<p>21.&nbsp;&nbsp; Falcaro M, Casta&ntilde;on A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in <span class=\"xn-location\">England<\/span>, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021 Nov 3:S0140-6736(21)02178-4.<\/p>"];
			$("#dvExtra").html(content_array[0]);})();